Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 3/20 | 0.46 |
| ▸ | REN | P00797 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861530 | 0.78 | EPHX2 (0.46) | ACE | |
| SCHEMBL1859118 | 0.78 | EPHX2 (0.46) | ACE | |
| SCHEMBL1867178 | 0.76 | KLK5 (0.49) | ATMRENCTSSACECTSL | |
| SCHEMBL7356966 | 0.76 | KLK5 (0.59) | ATMRENCTSSACECTSL | |
| SCHEMBL11374461 | 0.74 | ACE (0.62) | ATMCTSSACECTSLCTSB | |
| SCHEMBL11512962 | 0.74 | ACE (0.62) | ATMCTSSACECTSLCTSB | |
| SCHEMBL1861930 | 0.74 | KLK5 (0.43) | ATMRENCTSSACECTSL | |
| SCHEMBL7442960 | 0.74 | KLK5 (0.52) | ATMRENCTSSCTSLCTSB | |
| SCHEMBL9658402 | 0.74 | REN (0.49) | ATMRENCTSSACECTSL | |
| SCHEMBL9658400 | 0.74 | REN (0.49) | ATMRENCTSSACECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | ATM 2336/4885REN 298/4885CTSS 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.